Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00271596 · ClinicalTrials.gov registry record · Phase 2
Citalopram to Enhance Cognition in HD
A Phase 2 study, sponsored by University of Iowa.
- Completed
- Registry status
- Phase 2
- Development phase
- 33
- Enrollment target
NCT00271596 is a Phase 2 study that has completed, run by University of Iowa. The registered enrollment target is 33 participants.
The verdict
NCT00271596, a Phase 2 study, has completed, sponsored by University of Iowa.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 33 participants
- Enrollment target
Study Summary
This research plan proposes to conduct a double-blind, placebo-controlled pilot clinical trial in 36 adults with mild Huntington's disease (HD) to address the following research aims: 1. To determine the effect of citalopram compared to placebo in patients with early HD on executive function and other outcome variables including functional measures (health-related quality of life, work productivity, and self-reported attention), motor performance, and psychiatric status, 2. To study the relationship between executive function and functional status in patients with early HD after selective serotonin reuptake inhibitor (SSRI) treatment, and 3. To examine the effect of citalopram treatment on volumetric and metabolic (i.e, N-acetyl-aspartate concentration) measures in the neostriatum among patients with recently diagnosed Huntington's disease.
Interventions
- DRUG Placebo
- DRUG 20mg daily citalopram
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2005-11 |
| Est. Completion | 2011-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00271596
The ClinicalTrials.gov registry entry for NCT00271596 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Iowa, which has 228 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00271596 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00271596 about?
NCT00271596 is a clinical study titled "Citalopram to Enhance Cognition in HD". This research plan proposes to conduct a double-blind, placebo-controlled pilot clinical trial in 36 adults with mild Huntington's disease (HD) to address the following research aims: 1. To determine the effect of citalopram compared to placebo in patients with early HD on executive function and ot...
What is the current status of trial NCT00271596?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 33 participants. The study started on 2005-11. Estimated completion is 2011-11.
What interventions are being tested in trial NCT00271596?
The interventions under investigation include: Placebo (DRUG), 20mg daily citalopram (DRUG).
Who is sponsoring clinical trial NCT00271596?
This trial is sponsored by University of Iowa, which has 228 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.